Spero Therapeutics (SPRO) Capital Expenditures (2016 - 2021)
Spero Therapeutics posted quarterly Capital Expenditures of -$39000.0 for Q4 2021, down 425.0% year-on-year from $12000.0 in Q4 2020, and down 425.0% on a QoQ basis from $12000.0 in Q4 2020.
Spero Therapeutics (SPRO) has 6 years of Capital Expenditures data on file, last reported at -$39000.0 in Q4 2021.
- For the quarter ending Q4 2021, Capital Expenditures fell 425.0% year-over-year to -$39000.0; the trailing twelve-month figure through Dec 2021 stood at $24000.0 (down 84.71% YoY), and the FY2021 full-year result was -$39000.0, down 124.84% from the prior year.
- Capital Expenditures for Q4 2021 stood at -$39000.0, down from $12000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $129000.0 in Q4 2019 and bottomed at -$39000.0 in Q4 2021.
- The 5-year median for Capital Expenditures is $32000.0 (2018), against an average of $42090.9.
- The widest annual swing landed in 2018, when Capital Expenditures soared 3300.0%; it then sank 425.0% in 2021.
- A 5-year view of Capital Expenditures shows it stood at -$1000.0 in 2017, then jumped by 3300.0% to $32000.0 in 2018, then soared by 303.12% to $129000.0 in 2019, then tumbled by 90.7% to $12000.0 in 2020, then tumbled by 425.0% to -$39000.0 in 2021.
- The last three Capital Expenditures figures came in at -$39000.0 (Q4 2021), $12000.0 (Q4 2020), and $51000.0 (Q3 2020), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -39,000.00 |
| Dec 31, 2021 | -39,000.00 |
| Dec 31, 2020 | 12,000.00 |
| Dec 31, 2020 | 12,000.00 |
| Sep 30, 2020 | 51,000.00 |
| Sep 30, 2020 | 51,000.00 |
| Jun 30, 2020 | 15,000.00 |
| Jun 30, 2020 | 15,000.00 |
| Mar 31, 2020 | 79,000.00 |
| Mar 31, 2020 | 79,000.00 |
| Dec 31, 2019 | 129,000.00 |
| Dec 31, 2019 | 129,000.00 |
| Sep 30, 2019 | 17,000.00 |
| Sep 30, 2019 | 17,000.00 |
| Jun 30, 2019 | 87,000.00 |
| Jun 30, 2019 | 87,000.00 |
| Mar 31, 2019 | 81,000.00 |
| Mar 31, 2019 | 81,000.00 |
| Dec 31, 2018 | 32,000.00 |
| Dec 31, 2018 | 32,000.00 |
| Dec 31, 2017 | -1,000.00 |
| Dec 31, 2017 | -1,000.00 |
| Dec 31, 2016 | 261,000.00 |
| Dec 31, 2016 | 261,000.00 |